It’s a Rubik’s Cube.
That’s what New Enterprise Associates general partner Harry Weller told me about the monster venture capital firm’s philosophy regarding the management of its giant funds. The firm has raised more than $13 billion across 14 funds since its inception in 1977, the last three of which have been between $2.3 billion and $2.6 billion.
Everything about China is big, including its cancer problem. In some wealthier cities, like Beijing, cancer is now believed to be the most frequent killer. Air pollution, high rates of smoking, and notorious “cancer villages” scarred by industrial pollution are increasing death rates around the country. Liver cancer in particular is four times as prevalent as it is in the West, in part because one in 14 people in China carry hepatitis B, which puts them at risk. Of all the people worldwide who die of cancer each year, some 27 percent are Chinese.
Noah is a six-year-old suffering from a disorder without a name. This year, his physicians will begin sending his genetic information across the Internet to see if there’s anyone, anywhere, in the world like him.
Springboard’s Health Innovation Hub is a collaboration platform advancing the growth of digital health and life science companies led by women with significant potential for investment and partnerships.
About the Program
We seek women-led companies with a track record of milestone achievement. We are location- and stage-agnostic but seek solutions within several themes:
Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Notices:
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
Deloitte has launched the 2015 Top Technology Talent Competition for a fifth year seeking innovative ideas from college students on how technology can solve a business problem.
The winner of the 2015 Top Technology Talent Competition will win a trip to one of the Deloitte digital studios in the US, in addition to a six-week summer internship in Deloitte Ireland which will enable them to further develop their idea if they so choose.
MedImmune, the global biologics research and development arm of AstraZeneca, and the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) today announced the signing of a five-year agreement to jointly support research that will help advance drug discovery and manufacturing. The effort will focus on tools and measurements that will be used in the development and production of biopharmaceuticals, which are drugs and treatments derived from biological, rather than chemical, sources.
MedImmune, the global biologics research and development arm of AstraZeneca, announced today that it has joined the National Institutes of Health (NIH) Centers for Accelerated Innovations (NCAI) program as the first biotech/pharmaceutical company corporate partner.
The NCAI program was launched in September 2013 to improve how basic science advances and discoveries are translated into commercially viable treatments for patients. The National Heart, Lung, and Blood Institute (NHLBI) will provide $32.5 million in grants to establish three translational research Centers of Innovation in Boston, Cleveland and California, consisting of 14 top-tier research institutions. The program seeks to accelerate the commercialization of university-based technologies, and public private partnerships are critical to the success of the NCAI program.
Johns Hopkins University launched its Fast Forward business accelerator two years ago as a way to support the growth of its own entrepreneurial community, but also to help stimulate the Baltimore economy. It recently opened a second accelerator space on the East Side of Baltimore by its medical campus. It’s designed to equip life science startups with the kind of wet lab space that tends to come at a premium and is often too costly for early stage companies with an uncertain future.
MedImmune has joined the NIH’s Centers for Accelerated Innovations (NCAI) program as its first biopharma corporate partner.
The global biologics research and development arm of AstraZeneca said it will team up with NCAI awardees and help shape the program’s strategic direction. MedImmune said it may also review prospective NCAI technologies in collaboration with the awardees, and provide feedback regarding their commercial potential and early-stage development.
